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Background: Tobacco smoking is the leading avoidable cause of death in high-income countries. The
smoking-related disease burden is borne primarily by the least educated and least affluent groups. Thus, there is a
need for effective smoking cessation interventions that reach to, and are effective in this group. Research suggests
that modest financial incentives are not very effective in helping smokers quit. What is not known is whether large
financial incentives can enhance longer-term (1 year) smoking cessation rates, outside clinical and workplace
settings.
Trial design: A randomized, parallel groups, controlled trial.
Methods: Participants: Eight hundred low-income smokers in Switzerland (the less affluent third of the population,
based on fiscal taxation).
Intervention: A smoking cessation program including: (a) financial incentives given during 6 months; and (b)
Internet-based counseling. Financial rewards will be offered for biochemically verified smoking abstinence after 1, 2,
and 3 weeks and 1, 3, and 6 months, for a maximum of 1,500 CHF (1,250 EUR, 1,500 USD) for those abstinent at all
time-points. All participants, including controls, will receive Internet-based, individually-tailored, smoking cessation
counseling and self-help booklets, but there will be no in-person or telephone counseling, and participants will not
receive medications. The control group will not receive financial incentives.
Objective: To increase smoking cessation rates.
Outcome: Smoking abstinence after 6 and 18 months, not contradicted by biochemical tests. We will assess relapse
after the end of the intervention, to test whether 6-month effects translate into sustained abstinence 12 months
after the incentives are withdrawn.
Randomization: Will be done using sealed envelopes drawn by participants.
Blinding: Is not possible in this context.
Discussion: Smoking prevention policies and interventions have been least effective in the least educated,
low-income groups. Combining financial incentives and Internet-based counseling is an innovative approach that, if
proven acceptable and effective, could be later implemented on a large scale at a reasonable cost, decrease health
disparities, and save many lives.
Trial registration: Current Controlled Trials ISRCTN04019434.
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Tobacco smoking is the leading avoidable cause of death
and disease in high-income countries [1]. The smoking-
related disease burden is borne disproportionately by
the least educated and least affluent people, because of
the high smoking prevalence in these groups [2]. To re-
duce smoking-related health disparities, it is important
to design effective smoking cessation programs that
reach to low-income smokers. Since this group may be
harder to reach with traditional information and educa-
tion interventions [3,4], other approaches need to be
explored. For instance, a strong body of research shows
that both participation in addiction treatments and the
outcome of these treatments are enhanced by financial
incentives [5-8].
Rationale
Although people have incentives, both financial and
health-related, to adopt healthy behaviors, they often fail
to do so because these benefits are delayed or intangible.
The immediate costs and delayed benefits of behavior
change result in decision errors [9]. Giving financial
incentives may offset these decision errors and encour-
age healthy behaviors [5,9]. However, this approach is
seldom used, often because of moral considerations
(‘people should not be paid to do what they ought to do
by themselves’), or due to the assumption that relapse
will occur when the rewards are stopped. However, be-
cause of the high costs, both material and human, that
smoking imposes on society [10], serious consideration
must be given to any approach that may effectively and
cost-effectively encourage smoking cessation.
In the field of the addictions, interventions using fi-
nancial incentives are based on a robust theoretical and
empirical literature that regards addiction as a form of
conditioned behavior, and on well-established behavioral
principles of reinforcement [5,7,11]. Research in animals
and in humans shows that behavior can be shifted away
from drug seeking when drug avoidance is rewarded by
alternative reinforcers, if these reinforcers are presented
at the right time and are sufficiently rewarding [12]. Fur-
thermore, by promoting abstinence early in the treat-
ment and by improving treatment adherence and
retention, financial incentives enable people to take
fuller advantage of the other components of clinical
treatments [11]. Beside addictions, incentives have been
widely used in other fields of medical research, to im-
prove adherence to treatments and to make sure
patients present for outcome testing [13].
Efficacy of incentives for smoking cessation
Two recent meta-analyses concluded that contingency
management (i.e. financial incentives) is effective for
smoking cessation, producing an effect size of 0.31 to0.48, which can be considered as a substantial effect
[5,7]. A recent review also concluded that financial
incentives are efficacious for smoking cessation in eco-
nomically disadvantaged pregnant women [14]. A third
meta-analysis found that financial incentives increased
participation in smoking cessation programs, but had
no sustained effect on smoking cessation [8]. However,
the value of incentives used in most of the studies
included in the latter meta-analysis may have been insuf-
ficient to produce long-term results (median 120 USD,
range 10–750 USD). Furthermore, several of the studies
included in these meta-analyses were not designed to
produce long-term results. In order to be effective, the
value of incentives should be high enough to compete
with the reward from smoking and to compensate for
withdrawal symptoms (craving, depression, weight gain,
and so on) and for the loss of a valued activity. Research
showed that in substance abusers, there is a dose–
response association between the monetary value of
incentives and their effects on abstinence [7]. A recent
study showed that financial incentives of up to 750 USD
almost tripled smoking cessation rates after 12 months,
compared with a no-incentives control group (14.7% vs.
5.0%), even in highly educated, affluent workers at a
multinational company (65% of them earned> $100,000)
[6]. Thus, large incentives are likely to be effective to
elicit long-term (12 months) abstinence, even though it
is not clear whether these results apply to less edu-
cated and less affluent smokers, and outside workplace
settings [6].
Almost all of the published studies of financial incen-
tives for smoking cessation were conducted in clinical or
worksite settings, and most were relatively short-term
and used small incentives [5,7,8,14]. It has not yet been
tested whether financial incentives can enhance long-
term smoking cessation in a population-based setting,
that is, outside clinical and workplace settings. Finally,
there is a risk that the effects of incentives may dis-
appear after the incentives are stopped [8,15,16]. Our
study will address this important point.
Incentives: long-term effects
Incentives are external motivators and may not create an
enduring commitment to smoking abstinence. Thus,
there is a risk that incentives will produce temporary
compliance only, and that people will go back to un-
healthy behaviors once the incentive program is over
[15,16]. This problem is, however, not specific to finan-
cial incentives, as the effect of many therapeutic inter-
ventions will decline or disappear after the intervention
is stopped [17]. Nevertheless, smoking cessation inter-
ventions must be designed to produce permanent smok-
ing abstinence, as only permanent abstinence will reduce
smoking-related morbidity and mortality. Thus, in
Etter Trials 2012, 13:88 Page 3 of 10
http://www.trialsjournal.com/content/13/1/88addition to initially encouraging quit attempts and par-
ticipation in smoking cessation programs, the reward
schedule should reinforce long-term abstinence, in par-
ticular by offering the full amount of rewards only to
participants who achieve at least several months of ab-
stinence. Research shows that the relapse rate is rela-
tively small once smokers reach 6 to 12 months of
abstinence [17,18]. Thus, we will give the final incentive
after 6 months and will conduct the final follow-up after
18 months, to assess relapse 12 months after the end of
the incentives program.Cost-effectiveness of financial incentives
In the USA, the median cost-effectiveness of 500 medical
interventions was 42,000 USD per life year gained [19].
For comparison, the cost-effectiveness of smoking cessa-
tion treatments is in the range of 1,400-3,500 USD per
life year gained [20,21]. Thus, smoking cessation treat-
ments are about 10 to 20 times more cost-effective than
the average medical treatment. In fact, together with vac-
cines, tobacco dependence treatments are among the
most cost-effective of all medical interventions [22]. A
review found that the cost-effectiveness of nicotine re-
placement therapy (NRT) and bupropion is about 1,000
GBP (1,600 CHF) per quitter [20,21]. In our program,
financial incentives will cost up to 1,500 CHF per quitter,
but previous research shows that on average, participants
receive only about 40% to 50% of the maximum reward
available [16,23], that is, about 600 to 800 CHF if the
maximum reward is 1,500 CHF. This amount is substan-
tially lower than the cost per quitter for pharmacological
or medical treatments, considering that over 80% of
patients treated in clinical trials fail to quit, and that
incentives are paid to successful quitters only. Thus, the
planned intervention is likely to be as cost-effective as
other smoking cessation interventions, and substantially
more cost-effective than the average medical interven-
tion. Finally, previous research shows that financial
incentives for patients in addiction treatment are cost-
effective [24,25].Ethics
Risks to participants
There is no known risk associated with the Internet-
based behavioral support. We think it is unlikely that
many non-smokers will smoke before baseline just to
test positive on cotinine and CO, in order to be eligible
for this study. Besides smoking-related variables, no
health-related information will be collected. The files
containing the names of participants will be kept confi-
dential and will be accessible only to the first investiga-
tor, the computer expert in charge of managing the
online data collection system and the research assistant.Migros gift cards instead of cash
In order to make sure that the money is not spent on
cigarettes, alcohol, or drugs, incentives will be paid ex-
clusively in Migros gift cards. Migros is the largest
supermarket chain in Switzerland, and does not sell al-
cohol or tobacco. It also sells furniture, DIY, garden and
sport items, electronic equipment, and has restaurants.
Informed consent, approval
All participants will sign a consent form (on paper, not
online). Participants will receive the intervention at no
charge. The study was approved by the ethics committee
of the Geneva University Hospitals and is registered in
Current Controlled Trials (ISRCTN04019434).
Methods/design
Objectives
The objective is to test whether a smoking cessation
program combining financial incentives with Internet-
based, individually-tailored behavioral support improves
smoking cessation rates in low-income smokers, com-
pared with cessation rates observed in a no-incentives
control group, and to measure the size of this effect, 12
months after the incentives are stopped, that is, 18
months after the intervention starts. The secondary
objectives are: to study whether the outcome is influ-
enced by the characteristics of participants: age, sex and
education, tobacco dependence level, motivation to quit
(intrinsic/extrinsic [26]), and smoking history; to assess
the effect of financial incentives on quit attempts; and to
assess whether financial incentives improve use of the on-
line smoking cessation program.
Design of the trial
A two-arm, open-label, randomized controlled trial with
follow-up after 3, 6, and 18 months. We will compare an
intervention group that receives financial incentives plus
Internet-based support to a control group that receives
Internet-based support but no incentives.
Randomization
Randomization will take place after we receive the base-
line survey and consent form and after we verify eligibil-
ity. Randomization will be done with sealed envelopes
drawn by participants.
Allocation concealment
Participants cannot be blinded to their assignment
group. Online data collection will be automatic, and
thus, there will be no bias in online assessments. In
non-respondents to the online surveys, follow-up data
will be collected by postal mail, and in non-
respondents to the postal questionnaires, a minimal
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ettes/day) will be asked over the phone.
Sequence and duration of follow-up
Confirmed quitters in the intervention group will receive
financial rewards six times: after 1, 2, and 3 weeks, and 1,
3, and 6 months. We will conduct questionnaire surveys
and measure saliva cotinine and expired carbon monox-
ide (CO) levels in both study groups at baseline and after
3 and 6 months (end of the intervention), and after
18 months (that is, 12 months after the end of the inter-
vention, to assess post-intervention relapse) (Figure 1).
Timetable and project duration
The preparation phase will last 9 months, the enrolment
phase 18 months, the observation phase 18 months, and
the data analysis 3 months. Thus, the total duration of
the study is 4 years.
Data
Questionnaires
The questionnaires will be collected online, and for non-
respondents to the online surveys, by postal mail and
over the phone. The questionnaires will be brief and fo-
cused, in order to maximize participation. Four waves of
questionnaires will be collected in both study groups: at
baseline and after 3, 6, and 18 months.
The baseline questionnaire will cover:
– Age and sex, school years, occupation, income, body
weight and height.
– Smoking status, cigarette consumption, level of
tobacco dependence.
– Motivation to quit (intrinsic/extrinsic) [26], past quit
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Figure 1 Flowchart of study participants.– Current and past use of smoking cessation
treatments and medications.
– Address, phone number, e-mail, Internet access.
The follow-up questionnaires (after 3, 6, and 18 months)
will cover:
– Smoking status (any smoking in the past 7 days,
4 weeks, 6 and 12 months).
– Quit date in ex-smokers.
– In current smokers: cigarette consumption and level
of dependence.
– Quit attempts (number, duration, dates).
– Motivation to quit (intrinsic/extrinsic), confidence in
ability to quit.
– Smoking cessation treatments used since enrolment.
– Opinions, satisfaction with the intervention.
– Items bought with the gift cards by quitters in the
intervention group.
– Body weight.
Participants will automatically receive an e-mail message
inviting them to take part in the online follow-up surveys,
3, 6, and 18 months after their target quit date. Partici-
pants who report that they have not smoked any tobacco
in the past 7 days will be invited to make an appointment
within the next days for biochemical verification.
Cotinine, CO, and thiocyanate measurements
Biochemical verification is essential in financial incen-
tives programs. Cotinine and CO tests will be conducted
at baseline in all participants (to verify that they are smo-
kers), and at each follow-up (3, 6, and 18 months), in both
study groups (intervention and control), only in partici-
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will come to our center to provide CO and saliva. CO tests
will be performed with a Bedfont Micro Smokerlyzer, and
cotinine in saliva will be assessed with NicAlert tests strips,
that can detect cotinine levels >10 ng/mL [27]. Compared
with gas chromatography, NicAlert tests strips have a spe-
cificity of 95-96%, a sensitivity of 93-99%, a positive pre-
dictive value of 95%, and a negative predictive value of 93%
[27,28]. In self-reported non-smokers who report using
NRT at follow-up and have a negative CO test (0–3 ppm)
but a positive cotinine test (NicAlert level>=1, that is,
>10 ng/mL) [29,30], we will use thiocyanate to verify
smoking abstinence (cutoff: 100 μmol/L) [31,32]. For thio-
cyanate analysis, saliva samples will be collected in a plastic
vial (salivette, Sarstedt) and frozen until sent to the labora-
tory. Tobacco alkaloids (anabasine or anatabine) are more
specific than thiocyanate. However, analyses of anatabine
or anabasine are expensive and are not routinely con-
ducted in saliva. In this community setting, taking blood or
urine samples will not be feasible.
Procedure (see flowchart)
To improve participation in biochemical tests, participants
in both study groups will be compensated (Migros gift
card, value 25 CHF) for providing saliva and CO samples
at follow-up (not at baseline and not when another incen-
tive is given on the same visit). There will be a 6-day time
window for the biochemical verification for the first three
assessments (that is, after 1, 2, and 3 weeks): people will
have to provide the biochemical samples within 6 days of
each assessment point. The time window will be 1 month
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Figure 2 Flowchart for the verification of smoking abstinence.6 and 18 months assessments. These windows were set to
maximize participation, because in a community setting, as
opposed to workplace or clinical settings, all participants
may not strictly keep appointments.
CO and cotinine tests will be conducted in self-
reported quitters only. Those with negative CO tests
(0–3 ppm) and negative NicAlert tests (level = 0, that is
<10 ng/mL) will be declared quitters and will receive
their reward immediately, during the same clinic visit.
Those who have positive CO tests (>=4 ppm) will be
declared smokers. Those with negative CO tests (0–3 ppm)
but positive NicAlert tests (level>=1) will be asked
whether they are sure they actually quit. Those who
answer ‘yes’ and who currently use NRT will provide a
saliva sample for thiocyanate analysis. Those with nega-
tive thiocyanate results will be considered quitters (Fig-
ure 2). Using CO, cotinine, and thiocyanate allows for a
more stringent test of abstinence than in most previous
studies of incentives, which used only CO. Carbon mon-
oxide reflects tobacco use during the last few hours, and
cotinine and thiocyanate during the last few days only.
No biochemical test allows for the verification of abstin-
ence over more than a few days.
Selection and withdrawal of subjects
Enrolment strategies
Participants will be 800 low-income smokers. They will
be informed of the study via advertisements in the press,
on the Internet, in workplaces, hospitals, pharmacies,
clinics and medical and dentistry offices, by direct mail-
ing, and by direct contact with the study assistant in the
streets and at sports events. Advertisements will best 7 days) 
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low educated people (for example football and hockey
games, free newspapers). The advertisements will inform
participants of the possibility of earning up to 1,500
CHF for participating in a smoking cessation study.
After answering the online baseline questionnaire, parti-
cipants will visit our center, where eligibility will be
assessed. We define ‘low income’ as a documented tax-
able annual household income ≤50,000 CHF for single
people and<=100,000 CHF for married people, which is
the income of roughly the least affluent third of house-
holds in Geneva [33].
Subject inclusion criteria
1. > 18 years old.
2. Taxable income ≤50,000 CHF (single) or<=100,000
CHF (married), proven by most recent fiscal
taxation.
3. Smokes at least five cigarettes per day, every day.
4. Has smoked for at least 1 year.
5. Baseline CO reading of at least 10 ppm.
6. Baseline saliva cotinine reading of NicAlert level 1
or higher (>= 10 ng/mL).
7. Sets a quit date within 1 month and commits to quit
at that date by signing the quitter contract.
8. Commits to take part in all follow-up surveys and in
all biochemical tests.
9. Declares to understand and to accept the control
group procedure.
10. Signs informed consent form at each line.
11. Shows identity document with photo (a copy will
be kept in our records).
12. Has regular access to Internet and e-mail.
13. Commits to read e-mail daily during the study.
14. Valid e-mail address, postal address and telephone
number.
Subject exclusion criteria
– Not meeting all 14 inclusion criteria
In Switzerland, 80% of the general population had Inter-
net access in 2010, including 70% of low-income people
and 92% of low-income people younger than 35 years
[34]. Thus, requiring regular Internet access may result
in a selected subsample of low-income people, but only
in those older than 35 years, since in younger people, al-
most everyone has Internet access.
The intervention
Tests of financial incentives have almost always been
conducted in association with clinical treatment, rather
than as stand-alone treatments [7,8]. Thus, in addition tofinancial rewards, all participants will receive behavioral
support. The intervention will have five components:
1 Component for the intervention group only:
1. Financial incentives of up to 1500 CHF, paid to
those verified abstinent.
4 Components for both the intervention and the control
groups:
2. Internet-based smoking cessation program.
3. Self-help booklets.
4. Optional enrolment of a social supporter of their
choice.
5. Quitter contract with quit date (signed by
participant, supporter, and study assistant).
Thus, the study will test the effect of financial incen-
tives, over and above a psychosocial intervention com-
prised of an online program, booklets, a social supporter
(optional), and a quitter contract. This is a realistic inter-
vention requiring no medical staff (no physician, nurse,
or psychologist). There will be no in-person or telephone
counseling, and participants will not receive medication.
Thus, if proven effective, this intervention will be imple-
mentable at a large scale with reasonable resources.
Financial incentives
Value of rewards In substance abusers, greater monet-
ary values of incentives are associated with larger effects
on abstinence [7], and small rewards to not produce sus-
tained effects on smoking cessation [8]. Furthermore,
the only study that found a sustained (12–18 months)
effect of incentives on smoking cessation used large
incentives, of up to 750 USD (which corresponded to
950 CHF in 2005 values, when this study was con-
ducted) [6]. In an opinion survey in the US, when asked
how much money should be paid to smokers to quit
smoking, 53% of participants responded 0 USD, 36%
responded 50–500 USD and 11% responded >1,000
USD [35]. When we asked the same question to 120 visi-
tors of the Stop-tabac website, 26% responded 0 CHF,
22% responded 10–500 CHF, and 53% responded
>1,000 CHF. Based on this information, we will use
incentives of up to 1,500 CHF. However, previous re-
search shows that on average, participants in incentive
programs receive only about 40-50% of the maximum
reward available [16,23], that is, about 600–800 CHF if
the maximal amount available is 1,500 CHF. A reward of
1,500 CHF corresponds to 36% of the monthly income
of people who earn 50,000 CHF per year. For reasons
stated above, incentives will be paid in Migros gift cards,
not in cash.
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after a quit attempt is initiated, abstinence needs to be
reinforced early on [36]. Research shows that incentives
have a larger impact if they are delivered at high fre-
quency, soon after the target behavior takes place [11].
Thus, participants will be instructed to present at our
center for verification as soon as they achieve 1 week of
abstinence, so that abstinence can be reinforced soon
after it occurs. Abstinence will be reinforced weekly dur-
ing the first month, and then after 3 and 6 months.
Immediacy of rewards Research shows that rein-
forcement works best when the target behavior is fol-
lowed by the reinforcer without delay [37]. Delayed
rewards are discounted, and a smaller amount given
now is valued the same as a larger amount given later.
In substance abusers, rewards are about twice as effect-
ive when they are delivered immediately, during the
same clinic visit, than when the payment is delayed [7].
Thus, we will pay rewards immediately after conducting
the cotinine and CO tests, during visits at our center.
This is why we will use NicAlert tests strips that pro-
duce results within a few minutes [27].
Escalation and reset Research shows that escalating
systems produce longer periods of smoking abstinence
compared with constant rewards [38]. Because we want
to reward sustained abstinence rather than initial quit
attempts, we will use an escalating scheme and give
incentives six times during 6 months (100, 150, 200, 300,
350, and 400 CHF at 1, 2, 3 weeks and at 1, 3, and
6 months, respectively). If people smoke or miss an as-
sessment, the value of the next reward will be reset to
the value of the last reward they attained, and the escal-
ation scheme will start again at this value. Incentives will
be paid only to people with negative CO and cotinine in
saliva, assessed with NicAlert tests strips, and to NRT
users who have positive cotinine tests but negative CO
tests [27].
Behavioral intervention for both study groups
Quitter contract with quit date
A contract will be signed by each study participant, and
countersigned by the research assistant and by the op-
tional social supporter. In this contract, participants will
commit to quit at a target quit date set no later than
1 month after enrolment, and to make additional quit
attempts at a later date if the first quit attempt fails.
Social supporter
Participants who agree will designate a social supporter,
preferably a non-smoker, with whom they have a regular,
positive association (for example, spouse, friend, or
colleague). Social supporters will countersign theparticipant’s quit contract. Social supporters will sign a
consent form, receive a document describing their role
in the study, and answer a brief questionnaire to return
to us by mail, about their smoking status, age, sex, and
address.
Internet-based, automatic behavioral support (‘Coach’)
Participants in both study groups will have the opportun-
ity to enrol in an online ‘Coach’, which is an automatic,
interactive, smoking cessation program. The ‘Coach’ con-
sists of individually-tailored feedback reports, personal
pages with progress graphs and a series of e-mail mes-
sages sent automatically over 3 months [3,39]. Partici-
pants will also be encouraged to use the other services
available on the Stop-tabac.ch website (discussion for-
ums, ‘chats’, testimonials, fact sheets, and so on).
There will be no in-person behavioral support of tele-
phone support. However, participants will be able to call
the study assistant for administrative purposes.
Booklets
Participants in both the intervention and the control
group will receive a series of self-help booklets [3,40]. Fi-
nally, we will inform participants if any new, effective
treatment of tobacco dependence is discovered during
the study.
Control group procedures
After randomization, participants in the control group
will be informed about their group assignment, during
the enrolment visit. They will be advised to quit smoking
and will be encouraged to use the Stop-tabac website and
self-help booklets in the same manner as the intervention
group. They will be contacted again only for the follow-
up surveys and for the cotinine, CO, and thiocyanate
tests after 3, 6, and 18 months. In follow-up surveys, we
will ask participants in both study groups whether they
obtained smoking cessation support, and the type and
amount of support they obtained (Internet, quitline,
smoking cessation clinic, physician, medications, and so
on). In data analyses, this will enable us to control for the
amount of support received by participants.
Cessation induction vs. aid to cessation
Financial incentives may have two types of effects: they
may induce quit attempts in people who would not
otherwise have tried to quit (cessation induction); and
they may increase the success of quit attempts (aid to
cessation) [41]. Since all participants will commit to
make a quit attempt and set a quit date within 1 month
of enrolment, our trial will not be a good test of cessa-
tion induction, it will rather be an aid-to-cessation trial.
We will nevertheless assess the effect of the intervention
on quit attempts, as a secondary outcome.
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The primary outcome will be continuous smoking ab-
stinence between 6 and 18 months, that is, self-report of
no puff of tobacco in the previous 7 days at 6 months
plus self-report of no smoking between the 6- and 18-
month surveys, not contradicted by CO, cotinine, and
thiocyanate measurements. The date for follow-up sur-
veys will be tied to the target quit date set at baseline.
As secondary outcomes, we will also assess:
– Biochemically confirmed point prevalence of
abstinence after 3, 6 and 18 months.
– Abstinence at 3, 6, and 18 months using the ‘Russell
Standard’, a recently suggested standard for smoking
cessation trials [42].
– Quit attempts during the intervention phase
(number, duration and dates).
– Cigarette consumption, motivation to quit,
confidence in ability to quit.
– Use of the online smoking cessation program.
Methods for assessing and recording efficacy parameters
To avoid using paper, questionnaires will be collected
online. In non-respondents to the online surveys only,
questionnaires will be collected by postal mail and then
by phone.
Baseline data
After answering the online baseline questionnaire, partici-
pants will visit our center in Geneva, where smoking sta-
tus will be biochemically verified. No smoking cessation
counseling will be provided during the enrolment visit.
Follow-up after 3, 6, and 18 months
Participants will automatically receive by e-mail a request
to answer the online follow-up questionnaires, 3, 6, and
18 months after their target quit date. After six e-mail
reminders sent every 3 days, non-respondents to the on-
line surveys will receive the follow-up questionnaires by
postal mail. After three reminders by postal mail, non-
respondents will be contacted by phone [43]. The tele-
phone survey in non-respondents will cover only a
minimal subset of questions (smoking status, quit
attempts, quit date and cigarettes/day). After six unsuc-
cessful tries to reach non-respondents by phone at differ-
ent hours and days of the week, we will contact a next of
kin or a friend (whose address was provided at baseline
by participants who agree with this procedure) to locate
non-respondents. In our previous trials, this procedure
enabled us to obtain response rates of about 95% [40,44].
There is a risk that participants in the control group will
drop out of the study when they learn about their group
allocation, which would represent a threat to the validityof the study. We will make sure we obtain similarly high
response rates in both study groups at follow-up.
Biochemical verification
The outcome is self-reported prolonged abstinence that is
not contradicted by biochemical tests of recent abstinence.
After 3, 6, and 18 months, participants who report abstin-
ence (no puff of tobacco in the previous 7 days) will be
invited to come to our center to perform a CO test and
provide saliva samples for cotinine analysis and, if neces-
sary, thiocyanate analysis. The procedure described above
(multiple reminders by e-mail, postal mail, and telephone)
will also be used to invite participants for the biochemical
tests. After the reminders, a study assistant will offer to
smokers who claim abstinence but do not show up for
testing to meet them at their home or workplace or at a
public space, to collect the CO and saliva samples. The
saliva samples will be destroyed after the cotinine and
thiocyanate analyses.
Statistics
The main analysis will be a comparison of the propor-
tions of abstinent smokers in the intervention and con-
trol groups. We will use chi-square tests and odds ratios
with 95% confidence intervals to compare these propor-
tions. If covariates are needed due to imbalance despite
randomization, we will use multivariate logistic regres-
sion models instead. We will conduct subgroups ana-
lyses, and will use multivariate models to test whether
the outcome is influenced by participants’ characteristics.
We will assess whether motivation (intrinsic or extrinsic)
acts as a mediator in the association between incentives
and behavior [26]. Analyses will compare participants
who did or did not have a social supporter, or who did
or did not use the online Coach, to see if these influence
outcome or interact with treatment assignment.
Sample size calculation
Based on our previous research in a similar population,
we expect a quit rate of about 10% in the control group
[39,45]. Previous research showed that financial incen-
tives either have little long-term effect on smoking ces-
sation [8], or an effect size of 0.31 to 0.48 [5,7], but
larger incentives have a substantial effect (odds ratio> 3)
[6]. A sample size of 800 participants (2 x 400) will en-
able us to detect a difference between quit rates of 10%
in the control group and 17% in the intervention group
(odds ratio = 1.84, power = 80%, P= 0.05).
Intention-to-treat, missing data
For the primary outcome, participants will be evaluated
in an intention-to-treat analysis, with all randomized par-
ticipants in the denominator. Participants with missing
data at follow-up will be counted as smokers. We will
Etter Trials 2012, 13:88 Page 9 of 10
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tions for missing data. Based on our previous studies, we
expect 5% of missing data [46,47].
Discussion
Combining financial incentives with Internet-based behav-
ioral support is an innovative approach, feasible, easily dis-
seminated, and potentially cost-effective. This study will
help us understand whether financial incentives and the
Internet can be used to modify health-related behaviors in
a population-based setting, and it will provide valuable in-
formation on the categories of people in whom this inter-
vention is most effective and on the acceptability of this
intervention. This program is of particular interest for
low-income populations, in whom smoking prevalence is
particularly high. If this study proved that this intervention
is effective, this would suggest that, to reduce disparities
in smoking due to income and education, tobacco control
programs may shift prevention budgets from education
and information campaigns to a structured program com-
bining financial incentives with online behavioral support.
Therefore, this study has the potential to influence policy
decisions. If this program was proven effective, it could be
widely disseminated, have a substantial impact on smok-
ing cessation rates, decrease health disparities and save
many lives.
Trial status
The enrolment of participants started in August 2011
and will last until February 2013.
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